Results 151 to 160 of about 22,441 (303)

TACE with Lenvatinib and Pembrolizumab in Unresectable, Nonmetastatic Hepatocellular Carcinoma: Results from the LEAP-012 Trial. [PDF]

Radiol Imaging Cancer
Siddiqi NS.
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Beyond concealment: Translating placebo research into migraine care. [PDF]

Headache
Kleine-Borgmann J, Schmidt K, Bingel U.
europepmc   +1 more source

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio, Laura A. Cooney, Kohei Maeda, Phillip L. Campbell, Qi Wu, Camila I. Amarista, Alexander Stinson, Ray Ohara, Yang Mao‐Draayer, Michael L. Whitfield, Shiv Pillai, Poulami Dey, Johann E. Gudjonsson, Pei‐Suen Tsou, Dinesh Khanna, David A. Fox   +15 more
wiley   +1 more source

Updating UK clinical guidelines to incorporate the placebo effect in peri-operative care: challenges and opportunities. [PDF]

Front Pain Res (Lausanne)
Gregory E.
europepmc   +1 more source

On blaming the placebo [PDF]

Arthritis & Rheumatism, 1991
W V, Epstein, C J, Henke
openaire   +2 more sources

Pills or Placebos?

, 1999
Antelman, Seymour M., Trussell, James, Caggiula, Anthony R.Fish, Jefferson M., Weissman, Myrna M., Hankoff, L.D., Levine Joseph, Gershon, Samuel, Kazdin, Alan E.   +7 more
core   +1 more source

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid‐Refractory Macrophage Activation Syndrome Complicating Still's Disease

Arthritis &Rheumatology, EarlyView.
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom, Jordi Antón, Edward M. Behrens, Corey Best, Norbert Blank, Josefin Blomkvist, Scott W. Canna, Sonia Carriquí, Shanmuganathan Chandrakasan, Andrew Danquah, Ngoc‐Bao Duong, Brian D. Jamieson, Paivi Miettunen, Abiola Oladapo, Sampath Prahalad, Pierre Quartier, Grant Schulert, Anna Stoltenberg, Uwe Ullmann, Erika Van Nieuwenhove, Sebastiaan J. Vastert, Fabrizio De Benedetti   +21 more
wiley   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Arthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

What to do with anti-science influencers? [PDF]

Einstein (Sao Paulo)
Pasternak J.
europepmc   +1 more source